Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michelle R Mahoney

Showing results (41-50 of 47) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 47 results.
Journal of the National Cancer Institute|June 14, 2014
Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147Wilson I Gonsalves, Michelle R Mahoney, Daniel J Sargent, et al.
Cancer Prevention Research (Philadelphia, Pa.)|January 7, 2011
Randomized phase II trial of sulindac, atorvastatin, and prebiotic dietary fiber for colorectal cancer chemopreventionPaul J Limburg, Michelle R Mahoney, Katie L Allen Ziegler, et al.
JAMA|April 5, 2012
Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trialSteven R Alberts, Daniel J Sargent, Suresh Nair, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2004
Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group StudyMegan M Garrity, Lawrence J Burgart, Michelle R Mahoney, et al.
Clinical Trials (London, England)|December 1, 2020
Composite grading algorithm for the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)Ethan Basch, Claus Becker, Lauren J Rogak, et al.
Clinical Colorectal Cancer|February 12, 2014
Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147Jocelin Huang, Suresh G Nair, Michelle R Mahoney, et al.
The New England Journal of Medicine|December 22, 2018
Sorafenib for Advanced and Refractory Desmoid TumorsMrinal M Gounder, Michelle R Mahoney, Brian A Van Tine, et al.
Pageof 5

Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
Journal of the National Cancer Institute|June 14, 2014
Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147Wilson I Gonsalves, Michelle R Mahoney, Daniel J Sargent, et al.
Cancer Prevention Research (Philadelphia, Pa.)|January 7, 2011
Randomized phase II trial of sulindac, atorvastatin, and prebiotic dietary fiber for colorectal cancer chemopreventionPaul J Limburg, Michelle R Mahoney, Katie L Allen Ziegler, et al.
JAMA|April 5, 2012
Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trialSteven R Alberts, Daniel J Sargent, Suresh Nair, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2004
Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group StudyMegan M Garrity, Lawrence J Burgart, Michelle R Mahoney, et al.
Clinical Trials (London, England)|December 1, 2020
Composite grading algorithm for the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)Ethan Basch, Claus Becker, Lauren J Rogak, et al.
Clinical Colorectal Cancer|February 12, 2014
Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147Jocelin Huang, Suresh G Nair, Michelle R Mahoney, et al.
The New England Journal of Medicine|December 22, 2018
Sorafenib for Advanced and Refractory Desmoid TumorsMrinal M Gounder, Michelle R Mahoney, Brian A Van Tine, et al.
Pageof 5